GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » Tax Expense

ACON (Aclarion) Tax Expense : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Aclarion Tax Expense?

Aclarion's tax expense for the months ended in Sep. 2024 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.


Aclarion Tax Expense Historical Data

The historical data trend for Aclarion's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion Tax Expense Chart

Aclarion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
- - - - -

Aclarion Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aclarion Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aclarion  (NAS:ACON) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Aclarion Tax Expense Related Terms

Thank you for viewing the detailed overview of Aclarion's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclarion Business Description

Traded in Other Exchanges
N/A
Address
8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Executives
John Paul Lorbiecki officer: Chief Financial Officer 238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness director, officer: Chief Executive Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond officer: Chief Strategy Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch director 1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann director 130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann director, officer: Executive Chairman 8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks 10 percent owner 811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc 10 percent owner 7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc 10 percent owner 1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart director 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira director 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal director C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404